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Abstract
Few treatment options exist for metastatic prostate
cancer (PC) that becomes hormone refractory (HRPC).
In vitro, plant-derived MINA-05 caused dose-dependent
decreases in cell numbers in HRPC cell lines LNCaP-
C4-2B and PC-3, and in androgen-sensitive LNCaP-FGC,
DuCaP, and LAPC-4, by WST-1 assay. MINA-05 pre-
treatment significantly decreased clonogenic survival
in agar and on plastic at 1  and 2  IC50 for PC-3 (P <
.05 and P < .001, respectively), and at 1/2 , 1 , and 2 
IC50 for LNCaP-FGC cells (P < .001). MINA-05 also
induced G2M arrest of LNCaP-FGC and PC-3 cells (by
flow cytometry) and caused some apoptosis in LNCaP-
FGC (sub-G1 peak on flow, expression of activated
caspase-3) but not in PC-3 cells. Western blotting
indicated that these cell cycle changes were associated
with decreased levels of regulatory proteins cyclin B1
and cdc25C. MINA-05 given daily by gavage for 39 days
did not diminish primary orthotopic PC-3 growth in nude
mice, but decreased the extent of lymph node invasion
at higher doses. We conclude that MINA-05 induces
G2M arrest, inhibits cell growth, reduces PC cell re-
growth in vitro, and reduces lymph node invasion after
orthotopic PC-3 cell implantation in vivo. It has potential
as an adjuvant treatment for patients with PC.
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Introduction
Prostate cancer (PC) is currently the second highest killer of
Occidental men from cancer [1]. PC commonly metasta-
sizes to lymph nodes and bone and, once regional lymph
node involvement occurs, 85% of patients will develop
distant metastases within 5 years with a median survival
time of 1 to 3 years (http://www.cancer.gov/cancertopics/
pdq/treatment/prostate/healthprofessional). Metastatic dis-
ease is primarily treated by androgen ablation but recurs as
hormone-refractory PC (HRPC). Chemotherapy for such
patients is mostly palliative; new therapeutic strategies are
needed. Complementary therapies are used by up to 80% of
patients with cancer [2], emphasizing the need to delineate
their mechanisms of action, pharmacology, and toxicology [3].
Treatment with MINA-05, a plant extract developed by CK
Life Sciences Int’l Inc. (Hong Kong), has been shown to inhibit
the growth of subcutaneous PC-3 tumors in athymic nude mice
(Liu et al., personal communication). MINA-05 contains Wu
Wei Zi (Schisandra chinensis), soybean (Glycine max), Gua
Lou (Trichosanthes kirilowii Maxim), and yucca (Yucca schidi-
gera), ingredients shown to induce cell cycle arrest. S. chinen-
sis induces apoptosis of PC cells by inhibiting androgen
receptor expression [4]. Genistein, daidzein, and isoflavonoids
in soybean have potential for breast cancer prevention [5], and
genistein induces G2M arrest in MCF-7 cells [6]. In addition,
dietary genistein has been shown to improve survival, lower the
incidence of poorly differentiated PC, and reduce expression
of osteopontin in the prostate of transgenic mice with PC [7].
Cucurbitacins in Fructus trichosanthis inhibit growth of various
cancer cell lines [8] and of lung xenografts in nude mice [9].
The antioxidants resveratrol and yuccaol in Y. schidigera in-
hibit sarcoma cell proliferation in vitro [10]. Here we sought to
assess the effects of MINA-05 on the growth of human PC cell




MINA-05 (CK Life Sciences Int’l Inc Hong Kong), stored
sealed with desiccant at room temperature (RT), was dis-
solved in DMSO to a final concentration of 0.5% for treat-
ment. To ensure consistency of MINA-05 components between
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batches, HPLC profiling and liquid chromatography–mass
spectrometry (LC-MS) analysis based on markers selected
from the Chinese Pharmacopeia were performed.
LC separations were performed in a Waters (Milford, MA)
ACQUITY UPLCTM system using a 50  2.1-mm ACQUITY
BEH C18 1.7-mm column and a sample volume of 5 ml. The
mobile phase was composed of solvent A (0.1% formic acid)
and solvent B (acetonitrile) at a constant flow of 0.5 ml/min.
The gradient was programmed to increase the amount of
solvent B from an initial 40% to 95% in 3 minutes. The com-
position was held at 100% B for a further 1 minute (3.1–
4 minutes) before being returned to the initial condition until
6minutes. Gomisin Awas selected as one of themarkers.MS
was performed on a Micromass Quattro Premier LC/MS/MS
system fitted with an ESI+ interface and controlled by
MassLynx software (version 4.0) (Waters). For the MRM
transition mode, m/z 399.3 and 330.2 were selected as pre-
cursor and product ions, respectively. Cone voltage and col-
lision energy were optimized at 30 and 20 V, respectively. The
marker Gomisin A was present at 29 mg/g in MINA-05 ± 10%.
HPLC analysis was performed using a Waters HPLC
System (2796XC Bioseparations module) equipped with a
Waters 2996 PDA detector with MassLynx NT 4.0 software
for data acquisition and processing. HPLC separations of
samples were achieved with a Waters Xterra RP18 column
(3.9  150 mm, particle size of 5 mm) eluted at 1 ml/min
with a gradient elution of 5% to 95% acetonitrile in water for
18 minutes.
Cell Lines and Culture
PC-3 (from bone metastasis, p53 null [11]), LNCaP-FGC
(lymph node metastasis, p53 wild type [11]), and PZ-HPV-7
(p53 wild type with silent mutation at codon 113 [12]) were
obtained from the American Type Culture Collection (ATCC,
Rockville, MD). DuCaP and LNCaP-C4-2B were the gener-
ous gift of Professor Kenneth Pienta (University of Michigan,
Ann Arbor, MI) and LAPC-4 of Professor Charles Sawyers
(Memorial Sloan-Kettering Cancer Center, NY). PC-3 and
LNCaP-FGC were maintained in RPMI 1640 medium con-
taining 10% FBS. PZ-HPV-7 was maintained in keratinocyte
serum-free medium supplemented with bovine pituitary ex-
tract (0.05 mg/ml) and epidermal growth factor (0.005 mg/ml).
DuCaP (from dura mater metastasis [13], p53 mutation
A248W [14]) were cultured in Dulbecco’s modified Eagle’s
medium with 10% FBS and LNCaP-C4-2B in T medium [15].
LAPC-4 (from lymph node [16], p53 mutation, A175H P72R
[14]) was maintained in Iscove’s modified Dulbecco’s medium
supplemented with 10% FBS and 10 nmol/l dihydrotestos-
terone (Sigma Aldrich, Castle Hill, NSW, Australia). All cul-
ture media and supplements were obtained from Invitrogen
(Melbourne, VIC, Australia) unless indicated otherwise. Cells
were maintained under standard culture conditions.
WST-1 Assay
Cells were plated in triplicate in 96-well plates, left
48 hours, then treated with 0.244 to 200 mg/ml MINA-05,
0.5% DMSO vehicle, or medium alone. Cells were seeded
at the following concentrations (cells/well): PC-3 (4000),
LNCaP-FGC (1000), LAPC-4 (6000), DuCaP (7500),
LNCaP-C4-2B (7500) and PZ-HPV-7 (2000). After 72 hours,
viability was assessed by WST-1 assay, which quantifies
mitochondrial metabolic activity, as per the manufacturer’s
instructions (Takara, Madison, WI).
Cell Proliferation Assay
PC-3 (2.5  105 cells) and LNCaP-FGC (1.5  105 cells)
were plated in 150 cm2 flasks for 48 hours then treated with
a 2  IC50 dose of MINA-05 or 0.5% DMSO vehicle. After
15 minutes, 1, 4, 16, 24, and 48 hours, cells were harvested
by trypsinization with pooling of adherent and nonadherent
cells. Cells were washed twice in phosphate-buffered saline
(PBS) and viability was assessed with trypan blue. Cell pel-
lets were lysed in M-PER buffer (Pierce, Rockford, IL), snap-
frozen in liquid nitrogen, and stored at 20jC until analyzed
by Western blot.
Clonogenic Survival
Cells were pretreated with 1/2 , 1 , and 2  IC50 doses
of MINA-05 or 0.5% DMSO vehicle for 72 hours in 25 cm2
flasks. Cells were harvested and viability was determined
with trypan blue. For clonogenic assays on plastic (anchor-
age dependent), 250 viable cells per well were seeded in
six-well plates, then incubated without treatment for 7
(LNCaP-FGC) or 9 days (PC-3), based on known doubling
times. Media were refreshed every 3 days. Cells were then
stained with 0.5% crystal violet/20% methanol and colonies
of >50 cells were counted by inverted light microscopy. For
soft agar assays (anchorage independent), cells were har-
vested after treatment, and 5  104 cells in medium were
mixed 1:1 with 0.6% agar (0.3% agar) before seeding into
six-well plates precoated with 1.2% agar mixed 1:1 with
medium (0.6% agar). The plates were incubated for 14 days
and colonies of >50 cells in 10 random fields were counted
per well by inverse light microscopy.
Cell Cycle Analysis
PC-3 (2.5  105) and LNCaP-FGC (1.5  105) cells
per 150 cm2 flask were left 48 hours before treatment with
MINA-05 at 1/2 , 1 , and 2  IC50 or 0.5% DMSO vehicle
for 72 hours (<75% confluent). Adherent cells (collected by
trypsinization) were pooled with nonadherent cells and via-
bility was determined with trypan blue. Cells were washed
twice with PBS, fixed in ice-cold 70% ethanol, and stored at
4jC until use. Cells (5  105) were treated with 50 mg/ml
RNase A (Sigma), stained in 1.167 mg/ml propidium iodide
(Sigma) for 30 minutes at 4jC in the dark, then analyzed on a
FACSCanto flow cytometer (Becton Dickinson, Bedford, MA)
to analyze DNA content; 5  104 events were collected. Cell
cycle distribution was analyzed with FACSDiva software.
Immunohistochemistry
For activated caspase-3 staining, PC-3 and LNCaP-FGC
cells were grown on chamber slides at (1 to 2) 103 cells per
well for 48 hours, then treated with MINA-05 at 1/2, 1, and
2  IC50 or 0.5% DMSO vehicle for 72 hours before fixation
in ice-cold acetone. Positive control cells were treated with
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1 mg/ml cisplatin to induce apoptosis. Cleaved caspase-3
was detected using rabbit monoclonal antibody (5A1; Cell
Signaling Technology, Danvers, MA) then biotinylated goat
anti-rabbit IgG antibody (Vector Laboratories, Burlingame,
CA), and color was developed using a VECTASTAIN
ABC kit (Vector Laboratories) and DAB chromogen (Dako,
Carpinteria, CA). Over 200 nuclei were counted per well
and cells were scored for activated caspase-3 staining.
For pancytokeratin staining, frozen, acetone-fixed 5-mm
sections of lymph nodes embedded in Tissue-Tek ornithine
carbamoyltransferase (OCT) compound (Sakura Finetech-
nical, Koto-ku, Tokyo, Japan) on Superfrost Ultra Plus slides
(Menzel-Glaser, Raunschweig, Germany) were air-dried,
rinsed in PBS, quenched for endogenous peroxidase, and
blocked for nonspecific protein binding before being stained
with pancytokeratin antibody 1:5000 (Z0622; Dako) for
1 hour, and antirabbit antibody 1:100 (Vector Laboratories).
Color was developed using 1:100 HRP-conjugated avidin–
biotin complex (Vector Laboratories) then 1:50 DAB (Dako)
before counterstaining with Harris hematoxylin.
Western Blotting
Protein concentrations of cleared whole-cell lysates were
measured using BCA Protein Reagent Kit (Pierce). Proteins
were analyzed in equally loaded samples by Western blot,
using a rabbit polyclonal antibody to cdc2 phosphorylated
at Tyr15 (p-cdc2) (9111; Cell Signaling Technology; 1:1000),
a mouse monoclonal cdc2 antibody (sc-54; 1:200), a mouse
monoclonal antibody to cyclin B1 (sc-254; 1:200), and a
rabbit polyclonal antibody to cdc25C (sc-327; 1:400) (all from
Santa Cruz Biotechnology, Santa Cruz, CA) and a mouse
monoclonal antibody against human b-actin (AC-15, 1:7500;
Sigma). Briefly, samples were run on 10% sodium dodecyl
sulfate (SDS)–polyacrylamide gels and electrophoretically
transferred (SDS–PAGE) to nitrocellulose membranes (Bio-
Rad Laboratories, Hercules, CA). Nonspecific binding sites
were blocked with 5% skim milk powder diluted in PBS with
0.1% Tween 20 (SMP/PBST). Membranes were hybridized
with primary antibody followed by horseradish peroxidase–
linked goat anti-rabbit and goat anti-mouse secondary anti-
bodies (Santa Cruz) also diluted in SMP/PBST. Proteins
were visualized by enhanced chemiluminescence (Pierce).
Each blot was stripped with Restore Western blot stripping
buffer (Pierce) for reprobing with other antibodies.
Orthotopic PC-3 Tumor Xenograft Study
Permission for this study was obtained from the Animal
Ethics Committee, University of New South Wales (UNSW),
in line with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals. Sixty 6- to 7-week-old
male BALB/c nu/nu (nude) mice from the Biological Re-
sources Centre, UNSW, were housed at four to five per cage
under specific pathogen-free conditions. Mice were anes-
thetized with isoflurane (Abbott Laboratories, Botany, NSW,
Australia) and placed in a supine position, and the prostate
was exposed by laparotomy. PC-3 cells were orthotopically
implanted at 106 cells in 40 ml PBS (30 mice per day) before
closing and stitching the wound. Mice were randomized into
four experimental groups (n = 15). Daily gavage (ball-tipped
18-gauge needle) was started 3 days after tumor injection
at 2, 1, 0.5, or 0 mg MINA-05 in 400 ml 1% carboxymethyl
cellulose/2.5% DMSO daily. On day 21, five mice per group
were sacrificed and the remainder after 42 days. Prostates
were weighed and volumes were assessed by the formula
V = p/6(d1d2)
3/2, where d1 and d2 are diameters at right
angles. The draining, caudal, and renal lymph nodes were
frozen in Tissue-Tek OCTcompound (Sakura Finetechnical),
sectioned at 5 mm, and stained with hematoxylin and eosin
or antipancytokeratin antibody. Lymph nodes were scored
for intensity (1+, weak; 2+, moderate; 3+, strong) and pattern
(percent) of distribution of cytokeratin-positive PC-3 tumor
cell infiltration.
Statistical Analysis
GraphPad PRISM (GraphPad Software, San Diego, CA)
was used for statistical analysis. Data are expressed as
mean ± SD. In dose–response experiments, treatments were
compared by one-way analysis of variance then Tukey’s post-
tests. In time course experiments, two-tailed t tests were used;
P < .05 was considered significant. For lymph node inva-
sion, analysis of variance was used followed by Dunnett’s
multiple comparison test. For activated caspase-3 expression,
Kruskal–Wallis test and Bonferroni post hoc tests were used.
To have an optimal sample size, the data from three experi-
ments were analyzed together.
Results
MINA-05
Batch-to-batch reproducibility was assessed by com-
paring peak retention times of the major components and
ascertaining that they were within a window of 2% variation
in retention in keeping with standard assessment tech-
niques of the laboratory. A representative chromatogram
showing reverse phase HPLC separation of MINA-05 is
shown in Figure 1.
Growth Inhibition by MINA-05 of Human PC Cells
After 72 hours of MINA-05 treatment, mitochondrial meta-
bolic activities were significantly and dose-dependently de-
creased in all PC cell lines tested and in nontumorigenic
PZ-HPV-7 cells (Figure 2A). The IC50 values (mg/ml) were
13.39 (LNCaP-C4-2B), 46.34 (PC-3), and 1.21 (PZ-HPV-7) for
HRPC cell lines, and 25.11 (LNCaP-FGC), 35.53 (DuCaP),
and 4.24 (LAPC-4) for androgen-sensitive lines. Sensitivity to
MINA-05 did not correlate with androgen responsiveness,
site of isolation of the tumor cell line, or p53 status.
Treatment with 2  IC50 MINA-05 inhibited proliferation
of LNCaP-FGC and PC-3 cells (Figure 2, B and C). Both
showed no significant change in cell number over 48 hours
of MINA-05 treatment, whereas vehicle-treated cells, used
as controls in all experiments, increased exponentially from
24 hours. There were significantly fewer viable PC-3 and
LNCaP-FGC cells in MINA-05–treated flasks relative to con-
trols at 24 (P < .05) and 48 hours (P < .01).
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MINA-05 Treatment
MINA-05 treatment at 2  IC50 induced a modest, signifi-
cant decrease in the proportion of viable LNCaP-FGC cells
relative to controls after 16 to 48 hours (P < .05; Figure 3A),
but not in PC-3 cells (Figure 3B). Morphological changes
were seen after MINA-05 treatment in both LNCaP-FGC and
PC-3 cells (not shown), with flattening, cell enlargement, and
increased plastic adherence after 1 hour at lower MINA-05
Figure 1. Representative chromatogram showing reverse phase HPLC separation of MINA-05. Batch-to-batch reproducibility was assessed by comparing peak
retention times of the major components and ascertaining that they were within a window of 2% variation in retention in keeping with standard assessment
techniques of the laboratory.
Figure 2. Effect of MINA-05 treatment on proliferation of PC cell lines in vitro. (A) Cells seeded in 96-well plates were treated with 0.24 to 500 g/ml MINA-05
or 0.5% DMSO (vehicle). After 72 hours, effects on cell proliferation were determined by WST-1 assay. Additional wells assayed without treatment confirmed that
the DMSO vehicle did not affect cell viability (not shown). (B) LNCaP-FGC and (C) PC-3 cells were treated in 150 cm2 flasks with 2  IC50 MINA-05 or vehicle.
After the indicated time (hours) cells were harvested and cell viability was assessed by trypan blue exclusion. Data indicate mean ± SD (n = 3). *P < .05, **P < .01
relative to vehicle.
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doses. At 2  IC50, LNCaP-FGC cells became smaller and
rounded, whereas PC-3 cells appeared more dendritic.
MINA-05 Pretreatment Inhibited Colony Formation
Pretreatment of LNCaP-FGC cells with IC50 and 2  IC50
doses of MINA-05, but not at 1/2  IC50, significantly sup-
pressed colony formation in soft agar relative to vehicle-
treated wells (37 ± 2 colonies per 10 fields of view) with 0 ±
0 (P < .001), 0 ± 0 (P < .001), and 1 ± 1 (P < .001), respectively
(Figure 4A). MINA-05 pretreatment also resulted in abrogation
of colony formation on hard plastic from 310 ± 12 colonies per
well (vehicle-treated cells; Figure 4B) to 1 ± 1 (P < .001), 3 ± 1
(P < .001), and 8 ± 2 (P < .001), respectively.
Pretreatment of PC-3 cells with IC50 and 2  IC50 doses
of MINA-05 elicited a dose-dependent decrease in colony
numbers, whereas treatment at 1/2 IC50 did not significantly
alter clonogenicity relative to controls. Pretreatment with
MINA-05 at IC50 and 2  IC50 doses of MINA-05 decreased
colony numbers in soft agar from control numbers of 77 ±
6 colonies per 10 fields of view (Figure 4C) to 38 ± 12 (P <
.05) and 3.4 ± 1 (P < .001), and on hard plastic from 150 ±
25 to 41 ± 14 and 4 ± 1 colonies per well, respectively (both
P < .01; Figure 4C). MINA-05–resistant PC-3 colonies
(in agar) appeared larger than those in vehicle-treated cul-
tures (Figure 4A).
MINA-05 Induced Cell Cycle Arrest at the G2M Phase
Cell cycle distribution of LNCaP-FGC and PC-3 cells
was analyzed 72 hours after treatment with MINA-05 at
1/2  IC50, IC50, and 2  IC50 (Figure 5). G2M arrest was
seen after MINA-05 treatment at all doses in both cell lines,
with changes in the proportion of S-phase cells in LNCaP-
FGC but not PC-3 cells compared with control cells. LNCaP-
FGC cells accumulated in S phase after treatment at 1/2 
IC50 dose, but showed a decrease in the S-phase population
at IC50-MINA-05.
Apoptosis Was Increased in LNCaP-FGC but Not PC-3
Cells by MINA-05 Treatment
Apoptosis, as seen by the presence of a modest sub-G1
peak by flow cytometry, was induced in LNCaP-FGC cells
treated for 72 hours at IC50 and 2  IC50 doses of MINA-05
but not at 1/2  IC50 (Figure 5A). This was confirmed by an
increase in activated caspase-3–positive cells counted per
10 fields (±SD from n = 6) from 0.76 ± 1.07 in vehicle-treated
cells to 6.52 ± 5.59 [P = .051 and 7.45 ± 4.05 (P = .017) in
IC50 and 2  IC50 MINA-05 treated cells, respectively), but
not in those treated at 1/2  IC50 (0.49 ± 0.18, P = 1.00).
There was no sub-G1 peak in PC-3 cells (Figure 5B) nor an
increase in activated caspase-3–positive cells from vehicle-
treated (1.69 ± 0.06) to MINA-05–treated cells at any dose
(range, 1.24 ± 0.67 to 1.97 ± 2.26).
Western Blotting Analysis of G2M Regulatory Proteins
To investigate the mechanisms involved in G2M cell
accumulation after MINA-05 exposure, Western blotting
analysis for changes in the levels of key cell cycle factors
was undertaken. Cdc2 kinase assembly involves binding
to cyclin B1 and phosphorylation at Thr14 (phosphorylated
through Myt1) and Tyr15 (phosphorylated by Wee1) [17].
Mitosis is induced when cdc2–cyclin B1 complex accumu-
lates in the nucleus and is activated by dephosphorylation
of Thr14 and Tyr15 by cdc25 [17,18]. In this study, cyclin
B1 expression was decreased by MINA-05 treatment after
1 hour in LNCaP-FGC (Figure 6A) and after 4 hours in
PC-3 (Figure 6B) cells. G2M transition requires cdc25C to
dephosphorylate cdc2 [18]. Here, levels of cdc2 decreased
after 48 hours of treatment in PC-3 cells; p-cdc2 expres-
sion remained unchanged. Treatment of LNCaP-FGC cells
induced a transient decrease in cdc2 at 1 hour, with sus-
tained decrease from 16 to 48 hours. The ratio of p-cdc2 to
cdc2 protein levels was increased in LNCaP-FGC cells at 1,
16, 24, and 48 hours after treatment, indicating that cdc2
remained inactive. Cdc25C is detectable as three forms:
unphosphorylated cdc25C (fastest migratory form), phos-
phorylated on Ser16 (intermediate band), and the hyper-
phosphorylated (active) form (slowest migrating band)
present during mitosis [19]. No unphosphorylated cdc25C
Figure 3. Effects of MINA-05 treatment on viability of PC cells in vitro. (A)
LNCaP-FGC and (B) PC-3 cells were treated with 2  IC50 dose of MINA-05 or
0.5% DMSO (vehicle, V) for the time indicated (hours). Adherent and non-
adherent cells were pooled, and viability was determined by using trypan blue.
Graphs indicate mean ± SD of three independent experiments. *P < .05,
relative to vehicle.
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was detected in either vehicle- or MINA-05–treated LNCaP-
FGC cells. The phosphorylated form becomes undetectable
after 1-hour MINA-05 treatment, and both the phosphory-
lated and the active forms are undetectable from 4 hours
treatment onward (Figure 6A). In contrast, unphosphorylated
cdc25C is present in PC-3 cells but becomes undetect-
able after 1-hour MINA-05 treatment. From 16 hours on-
ward, all forms of cdc25C disappear with MINA-05 treatment
Figure 4. Effect of MINA-05 pretreatment on colony formation of PC cell lines in vitro. LNCaP-FGC and PC-3 cells were treated with MINA-05 at 1/2  IC50, IC50, or
2  IC50 concentrations, or 0.5% DMSO (vehicle), in triplicate. After 72 hours, cells were harvested, cell viability was determined by trypan blue exclusion assay,
and viable cells were seeded for clonogenic assays (A) in soft agar and (B) on plastic. (C) Total number of colonies (>50 cells) was counted by using an inverted
light microscope (original magnification, 38.4). Graphs indicate mean ± SD of three independent experiments. *P < .05, **P < .01 relative to vehicle.
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(Figure 6B). The decrease in cdc25C levels was not associ-
ated with an increase in p-cdc2 levels in PC-3 cells, which
may indicate that levels of the cdc2 kinases Myt1 and Wee1,
which maintain phosphorylation at Tyr15 and Thr14, respec-
tively, on cdc2, are also altered by MINA-05 treatment. This
was not assessed in this study.
Treatment with MINA-05 Inhibited Lymph Node Invasion
by PC-3 Cells In Vivo
Starting 3 days after intraprostatic injection of PC-3 cells,
treatment by gavage with MINA-05 at 0.5, 1, or 2 mg/d or
vehicle was performed daily for 39 days. There were six
unrelated deaths. Mice were sacrificed at 21 or 42 days
postimplantation to examine the effects of treatment. At
21 days, prostate tumor weights (mean, 60.3 mg; range,
32.3–86.5 mg) and volumes (mean, 69.5 mm3; range, 32.3–
86.5 mm3) varied, but showed no significant differences be-
tween treatment groups. After 42 days, tumors, present in
34 of 34 mice, were slightly smaller after MINA-05 treat-
ment (0.5 mg/d: 112 mg [76–151]; 1 mg/d: 100 mg [46–144];
2 mg/d: 119 mg [80–163]) compared with vehicle (126 mg
[84–159]) but with no significant differences between
groups. Enlargement of intraperitoneal lymph nodes oc-
curred in six of nine vehicle-treated mice, seven of nine, six
of eight, and eight of eight mice treated with 0.5, 1 mg/ml,
and 2 mg/d MINA-05, respectively. There was no significant
difference in the size of the enlarged lymph nodes in the dif-
ferent treatment groups. The pattern of PC-3 cell invasion
assessed by pancytokeratin staining within lymph nodes
was diffuse (Figure 7, A–C) or peripheral (Figure 7D).
The percentage of pancytokeratin-positive cells indicated
that lymph node invasion was decreased in mice on higher
MINA-05 doses (1–2 mg/d) compared with vehicle treat-
ment. From examining 21 to 24 lymph nodes per group,
mean percentage invasion was reduced from 44.2% in con-
trol mice (range, 20–90%) and 53.7% (range, 20–90%)
(P > .05) in mice given 0.5 mg/d to 34.3% (range, 10–
60%) (P < .05) and 30.5% (range, 0–50%) (P < .01) in mice
given 1 and 2 mg/d, respectively (Figure 7E ).
Discussion
MINA-05 was shown to inhibit cell proliferation in human
androgen-sensitive and HRPC cell lines, as well as in
immortalized normal prostate cells. Sensitivity to MINA-05
did not correlate with p53 status, androgen responsiveness,
or the metastatic site from which the cell line came. This
effect was associated with cell cycle arrest in G2M and an
increase in apoptosis at high doses in LNCaP-FGC but not
in PC-3 cells.
Abrogation of colony formation (Figure 4) occurred in
LNCaP-FGC cells at doses inducing f10% decrease in
cell number by WST-1 assay (Figure 2). The data suggest
that MINA-05 may slow cell proliferation with the surviving
population of LNCaP-FGC cells entering irreversible cell
cycle arrest or commitment to a cell death pathway. The
presence of a sub-G1 population of LNCaP-FGC cells and
cleaved caspase-3 staining suggests induction of apoptosis
Figure 5.MINA-05 treatment increases G2M population in PC cells in vitro. (A) LNCaP-FGC and (B) PC-3 cells were treated with
1/2  IC50, IC50, or 2  IC50 doses
of MINA-05 or 0.5% DMSO (vehicle, V) for 72 hours as shown. Adherent and nonadherent cells were harvested, stained with propidium iodide, and analyzed using
FACSCanto. Representative results from three independent experiments are shown.
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by MINA-05 at higher doses. As this did not occur in PC-3
cells, MINA-05 may inhibit PC-3 cell growth through a
mechanism other than apoptosis.
G2M arrest occurred after MINA-05 treatment in both
LNCaP-FGC and PC-3 cell lines. We used Western blotting
for expression of key regulators of G2M transition to deter-
mine the mechanism. Activation of nuclear cdc2/cyclin B1
complex by dephosphorylation of cdc2 at Thr14 and Tyr15 by
cdc25C is required for entry into mitosis [17]. DNA damage
through irradiation or treatment with drugs such as etoposide
interferes with cdc2 dephosphorylation by cdc25C phospha-
tase [20]. Loss (LNCaP-FGC) or decrease (PC-3 cells) of
cdc25C 1 hour after treatment with MINA-05 indicates that it
might cause DNA damage, with kinetics like those seen with
etoposide on CHO cells [21]. Inactivation of cdc25C can
involve phosphorylation through protein kinases Chk-1 and
-2 [17]. DNA damage may also turn on phosphorylation of
Tyr15 on cdc2 by Mik1 [22]. These mechanisms were not
investigated further in this study.
Cyclin B1 is ubiquitinated and degraded late in mitosis
[23,24]. We have shown that MINA-05 treatment decreased
cyclin B1 protein to undetectable levels in both LNCaP-FGC
and PC-3 cells (Figure 6). Levels of phosphorylated (inac-
tive) cdc2 were not substantially changed by treatment of
PC-3 cells before 24 hours. Levels of p-cdc2, compared
with total cdc2 levels, were markedly increased in treated
LNCaP-FGC cells relative to vehicle controls; this was as-
sociated with decreased cdc2 phosphatase, cdc25C. This
suggests that MINA-05 induces cell cycle arrest primarily
by decreasing cdc2/cyclin B1 activity through decreasing
cyclin B1 levels and, in LNCaP-FGC cells by decreasing
total cdc2 levels and increasing inactive p-cdc2. Alterna-
tively, MINA-05–induced cell cycle arrest may occur late
in mitosis, when cyclin B1 levels are decreased. Arrest in
M phase by antitubulin agents such as paclitaxel involves
activation of cdc2 and an increase in cyclin B1 levels [25],
effects that were not seen here. This suggests that MINA-05
is not causing mitotic arrest via effects on microtubules.
Figure 6. Expression of cell cycle– regulatory proteins after MINA-05 treatment. (A) LNCaP-FGC and (B) PC-3 cells were treated with 2  IC50 MINA-05 or vehicle
for the time indicated (hours), and the adherent and nonadherent cells were collected and lysed. Total protein (60 g) was subjected to SDS-PAGE and Western
blotting analysis by using antibodies against p-cdc2, cdc2, cyclin B1, and cdc25C. Representative results are shown.
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G2M arrest in p53 null cells tends to be transient [26].
Human colorectal cancer HCT116 cells, in which p53 had
been inactivated by homologous recombination, entered
temporary G2M arrest after ionizing radiation, whereas iso-
genic cells with functional p53 showed prolonged G2M arrest
[27]. After the p53-null cells escaped arrest, the proportion
of cells in mitosis was higher than in untreated cells [25].
This may explain our observation in PC-3 cells, which are
p53 null [11], where pretreatment with IC50 MINA-05 resulted
in formation in agar of colonies larger than after pretreatment
with vehicle alone. G2M arrest in PC-3 cells after MINA-05
treatment was not accompanied by a decrease in S-phase
cells compared with controls, suggesting that PC-3 cells
are not completely arrested after treatment (Figure 5). Inhi-
bition of cdc2 is one of the means by which p53 blocks entry
at the G2 checkpoint [26]. Levels of cdc2 were only margin-
ally decreased after 48 hours of treatment of PC-3, com-
pared with rapid effects in LNCaP-FGC cells that express
phenotypically wild-type p53 (Figure 5). PC-3 cells treated
at lower concentrations of MINA-05 may escape G2M arrest
and proliferate to form colonies, whereas treatment may in-
duce irreversible arrest in wild-type p53 LNCaP-FGC cells,
preventing colony formation (Figure 4).
Despite the finding that PC-3 cells were less sensitive to
growth inhibition by MINA-05 than by LNCaP-FGC, there
was an interesting response in vivo after orthotopic im-
plantation. PC-3 cells were selected for these studies as
they spontaneously spread to local lymph nodes. Whereas
MINA-05 treatment did not inhibit primary tumor growth,
there was significant inhibition of the extent of tumor inva-
sion into local lymph nodes by higher doses (1–2 mg/d)
of MINA-05. Because the mice were immunodeficient, this
Figure 7. PC-3 cell invasion of local lymph nodes after orthotopic implantation in nude mice. Photomicrographs showing pancytokeratin-positive PC-3 tumor cells
(brown) invading local lymph nodes (LN) after intraprostatic injection in nude mice. (A, B, C) Diffuse invasion in vehicle-treated mouse (original magnification, 40).
Insets show low-power staining and area selected at higher power. (D) Peripheral LN invasion in mouse treated with 2 mg/day MINA-05 (original magnification,
10). 1, Positive cytokeratin PC-3 tumor cell metastasis in lymph node. 2, Lymphocytes in paracortical area. (E) Graph showing percent infiltration of LN in vehicle-
or MINA-05– treated mice bearing orthotopic PC-3 tumors. Bars represent mean values.
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reflects a direct effect on the tumor cells, rather than being
an immune-mediated effect. The data suggest that higher
doses of MINA-05 may inhibit lymph node metastases.
Cells in G2M are more radiosensitive than cells in other
phases of the cell cycle [28]. Transient induction of G2M
arrest thus has the potential to increase sensitivity to radio-
therapy, suggesting that MINA-05 has a potential role as a
radiosensitizer. Overall, the data indicate that MINA-05
treatment has advantages for patients with PC, and further
investigation to determine potential synergy with other
agents, such as radiotherapy, is warranted.
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